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A b s t r a c t
Background: Increased ultrasound Doppler renal resistive index (RRI) is a marker of atherosclerotic and hypertensive organ 
damage both at renal and systemic level. 
Aim: To evaluate RRI in patients with true resistant hypertension (TRHT) in the RESIST-POL study.
Methods: From 204 patients diagnosed with TRHT in the RESIST-POL study, 151 patients (90 male, 61 female, mean age: 
47.7 ± 10.4, range: 19–65 years) without secondary hypertension were included into the analysis. All patients were charac-
terised by estimated glomerular filtration rate > 60 mL/min/1.73 m2 and no history of diabetes prior to the study. As a control 
group we included 50 age- and gender-matched patients (35 male, 15 female, mean age: 46.8 ± 10.4, range: 19–65 years) 
with primary well-controlled hypertension. The groups also did not differ in respect to the number of years of known history of 
hypertension. The RRIs were evaluated on the basis of the Doppler ultrasound examination. Increased RRI was defined as ≥ 0.7. 
Results: Both groups did not differ in terms of renal function. Patients with TRHT were characterised by higher RRI as com-
pared with the group with well-controlled hypertension (0.62 ± 0.05 vs. 0.60 ± 0.05, p < 0.05). In the TRHT group RRI 
correlated significantly with age, clinic and ambulatory blood pressure measurement, diastolic blood pressure (DBP) levels, as 
well as with clinic pulse pressure (PP) (r = 0.297; p = 0.001), with daytime (r = 0.355; p < 0.001) and nighttime (r = 0.313; 
p < 0.001) PP, and with fasting glucose concentration (r = 0.215; p = 0.008) and E/E’ ratio (r = 0.289; p = 0.001) on 
echocardiography. RRI values were significantly higher in TRHT patients with newly diagnosed diabetes as compared with 
TRHT patients without diabetes (0.65 ± 0.05 vs. 0.62 ± 0.05, p = 0.022). Age, daytime DBP, daytime PP, and E/E’ ratio 
but not fasting glucose concentration correlated independently with RRI in the model. Among patients with TRHT, patients 
with increased RRI were characterised by older age (52.2 ± 4.9 vs. 47.3 ± 10.6 years, p = 0.012), higher body mass index 
(32.8 ± 6.0 vs. 29.7 ± 4.5 kg/m2, p = 0.034), as well as lower daytime and nighttime DBP values and lower daytime and night-
time heart rate, as compared to patients with RRI < 0.7. The TRHT patients with increased RRI as compared to patients with 
RRI < 0.7 were characterised also by higher daytime and nighttime PP. Both groups did not differ in respect of renal function.
Conclusions: Our study showed that the patients with TRHT were characterised by significantly higher RRI values as compared 
to the subjects with well-controlled hypertension. It may also be suggested that in the subjects with TRHT renal vascular resis-
tance is related to blood pressure values, selected echocardiographic abnormalities, and some surrogate markers for metabolic 
and cardiovascular events, including fasting glucose plasma concentration and PP, respectively.
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INTRODUCTION
The Doppler-derived renal resistive index (RRI) has been 
used in a variety of clinical settings including the detection 
and management of renal artery stenosis or evaluation of 
progression risk in chronic kidney disease. More recently, 
evidence has been accumulated showing that an increased 
RRI not only reflects changes in intra-renal perfusion but also 
is related to systemic haemodynamics and the presence of 
subclinical atherosclerosis [1–4].  
On the basis of these results, the evaluation of RRI has 
been proposed in the assessment and management of patients 
with primary hypertension (HT) to complement other signs 
of renal abnormalities. Increased RRI indicates the presence 
of hypertensive and atherosclerotic organ damage such as 
left ventricular hypertrophy (LVH) and carotid intima-media 
thickening and may therefore be taken as an indicator of 
increased cardiovascular risk profile [5–11]. 
Renal resistive index proved also to be an independent 
predictor of worse cardiovascular and renal outcomes, espe-
cially when combined with reduced estimated glomerular 
filtration rate (eGFR). Furthermore, an increased RRI has 
been demonstrated to predict the onset of diabetes mellitus 
in patients with primary HT [8, 10, 12, 13].
It should be noted that the indices of renal perfusion 
have not been extensively studied in patients with resistant 
hypertension (RHT). A recent study indicates that in patients 
with therapy-resistant hypertension RRI reflects functional 
and structural vascular parameters, and measurement of RRI 
in addition to low-grade albuminuria complements screening 
for target organ damage in RHT [10].  
Therefore, the aim of our study was to evaluate RRI values 
in patients with true RHT in relation to ambulatory blood pres-
sure measurement (ABPM) values, biochemical parameters, 
and echocardiographic parameters depicting early target 
organ damage. We also compared RRI values of patients with 
true RHT with age-matched patients with well-controlled HT. 
METHODS
Study population
Evaluated patients were enrolled in the RESIST-POL study. 
The inclusion criteria were as follows: age 20–65 years, 
RHT confirmed on ABPM — mean daytime blood pressure 
(BP) > 135/85 mm Hg while on three antihypertensive drugs 
in optimal doses (including diuretic) — meeting the definition 
of true RHT. The exclusion criteria were: a history of other 
cardiovascular diseases (ischaemic heart disease, heart failure, 
transient ischaemic attacks, and previous stroke), decreased 
eGFR< 60 mL/min/1.73 m2, neoplastic diseases, previous 
diagnosis of diabetes mellitus, alcohol or medicine addictions, 
advanced changes in the skeletal system, malignant HT, preg-
nancy, and lack of cooperation or agreement to participation 
in the study. The study protocol conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki and was approved 
by the local Research Ethics Committee. Written informed 
consent was also obtained from each patient [14–18]. 
Since the principle goal of our present study was to evalu-
ate the RRI in patients with RHT with regard to selected clini-
cal parameters, we decided to exclude cases with secondary 
causes of HT characterised by other underlying mechanisms 
that could independently influence the RRI pattern. There-
fore, from the original group of 204 patients with RHT we 
excluded 49 patients with secondary HT and five patients in 
whom renal arteries Doppler evaluation was not suitable for 
further analysis.
The full protocol and main results of the RESIST-POL 
study have already been published [16]. In brief, patients 
with true RHT were screened for coexisting conditions includ-
ing metabolic abnormalities and obstructive sleep apnoea, 
secondary causes of HT, as well as being evaluated for target 
organ damage. As the methodology of the RESIST-POL study 
has been described extensively previously, we summarise 
below the definitions and methods used for the purpose of 
this analysis [16].
As a control group we included in our study 50 patients 
with well-controlled essential HT, being matched for age and 
gender. As criteria of BP control we assumed daytime ABPM 
levels below 135 mm Hg and 85 mm Hg for systolic and 
diastolic BP, respectively [19]. 
Office BP measurements
Blood pressure was measured by a trained nurse, with the 
patient in a sitting position after a 5-min rest, using an au-
tomated device (Omron 705IT, Omron Co., Kyoto, Japan). 
Based on the upper arm circumference an appropriately sized 
cuff was placed on the arm with the lower edge of the cuff 
2 cm above the antecubital fossa. Three consecutive read-
ings were performed. In cases where the difference between 
readings was higher than 10 mm Hg, further measurements 
were taken to obtain three consecutive consistent readings, 
the average of which was then recorded.
Ambulatory blood pressure monitoring 
In all patients the ABPM was recorded using SpaceLabs 
90207 or 90217 (Redmond, Washington, USA). Readings 
were obtained every 15 min during the day (06:00–22:00) 
and every 30 min during the night (22:00–06:00). Average 
24-h daytime and nighttime systolic BP, 24-h daytime and 
nighttime diastolic BP, and average 24-h heart rate (HR) were 
analysed. Nocturnal decrease in BP was quantified as the rela-
tive decrease in nocturnal BP for both systolic and diastolic 
BP: [(daytime pressure – night-time pressure)/daytime pres-
sure] × 100 and expressed as a percentage. Subjects were 
classified as dippers if the proportional decrease from waking 
to sleeping BP was ≥ 10%.
www.kardiologiapolska.pl
Aleksander Prejbisz et al.
144
Laboratory methods
Biochemical evaluation of blood samples taken after overnight 
fasting were determined by routine methods, and included 
sodium and potassium, lipids, blood count, fasting plasma 
glucose (FPG), creatinine, and uric acid. eGFR was calculated 
using the Modification of Diet in Renal Disease formula 
[20]. Albuminuria was assessed using a 24-h urine collec-
tion. Microalbuminuria was defined as 24-h albumin excre-
tion > 30 mg. Glucose and lipid metabolism abnormalities 
were diagnosed on the basis of the 2007 European Society 
of Hypertension/European Society of Cardiology (ESH/ESC) 
guidelines [19]. For diagnosis of metabolic syndrome, three of 
five criteria had to be met: (1) BP ≥ 130 mm Hg/≥ 85 mm Hg 
— this criterion was met for all patients; (2) abdominal obesity 
— waist circumference, male > 102 cm, female > 88 cm; 
(3) high density lipoprotein cholesterol, male  < 1.0 mmol/L, 
female < 1.2 mmol/L; (4) triglycerides > 1.7 mmol/L; and 
(5) FPG ≥ 5.6 mmol/L [19].
Renal ultrasound and Doppler studies
Ultrasonography examination and duplex Doppler imaging 
were performed with a Philips HD11 scanner with 2–4 MHz 
phased-array transducer. Patients were scanned in the supine 
position while in the fasting state. The intrarenal arteries were 
visualised in the colour duplex mode. Doppler ultrasono-
graphy spectral analysis included mean RRI and pulsatility 
index (PI). RRI was calculated as the difference between the 
peak systolic and end-diastolic blood velocities divided by 
the peak systolic velocity. PI was calculated as follows: peak 
systolic velocity – end diastolic velocity / mean velocity. RRI 
and PI were obtained from three Doppler curves at different 
sites of the each kidney. For calculations, the software of the 
duplex scanner was used. Measurements were made by two 
experienced investigators blinded to the clinical status of the 
patients. Interobserver and intraobserver coefficients of vari-
ance of RRI were 5.6% and 4.7%, respectively (n = 12) [21]. 
Echocardiography 
All patients underwent a complete transthoracic echocardio-
graphic study with a GE Medical System Vivid 7 (GE Health-
care) with a 2.5 MHz transducer. M-mode, two-dimensional, 
tissue Doppler echocardiography was used. The values of all 
echocardiographic parameters were obtained as the average 
of three consecutive cardiac cycles. The left ventricular (LV) 
mass (LVM) was calculated using the modified American 
Society of Echocardiography cube formula proposed by De-
vereux. Left ventricular mass index (LVMI) was obtained by 
normalising LVM to body surface area (BSA). LVH was defined 
as a LVMI ≥ 110 g/m2 for women and ≥ 125 g/m2 for men 
[19]. LV systolic function was evaluated by LV ejection fraction 
(LVEF) using biplane Simpson formula. LV diastolic function 
was evaluated by mitral inflow values and tissue Doppler im-
aging (TDI) velocities. Mitral inflow velocities were measured 
from the apical four-chamber view, with the sample volume 
placed at the mitral valve leaflet tips. The transmitral early 
diastolic (E-wave) and atrial (A-wave) velocities were meas-
ured and the E/A ratio was calculated. TDI examination was 
performed from the apical four-chamber view with the sample 
volume placed along the myocardial lateral wall 1 cm above 
the mitral annulus. Furthermore, the early diastolic velocity (E’) 
was measured and the E/E’ ratio was calculated [14, 15]. 
Statistical methods  
Data analysis was carried out using statistical software PASW 
Statistics 18 (SPSS Inc., Chicago, IL, USA). The results are 
presented as mean ± one standard deviation, or median 
and interquartile range. The values of variables between 
groups were compared — continuous and discrete variables: 
Student’s t test or Mann-Whitney test; categorical variables: 
c2 test or Fisher exact test. Parameters identified as statisti-
cally significant based on univariate analysis (p < 0.05) were 
included in the multivariate linear regression model in order 
to determine the combined effect of several variables on 
the renal resistive index. P < 0.05 was considered statisti-
cally significant.
RESULTS 
The clinical characteristics of subjects with RHT and controlled 
HT are shown in Table 1. Patients with RHT, as compared 
with patients with controlled HT, were characterised by 
higher body mass index (BMI), higher frequency of abdominal 
obesity, higher BP levels in clinic measurements and ABPM, 
as well as higher FPG, low-density lipoprotein cholesterol 
levels, and number of antihypertensive drugs. There were 
no differences in age, gender distribution, known duration 
of HT, creatinine serum concentration, and eGFR between 
the groups (Table 1). In 16 (10.6%) patients with true RHT 
diabetes mellitus was diagnosed. Diabetes mellitus was not 
found in any of the patients with controlled HT. A compari-
son of echocardiographic parameters between RHT patients 
and the well-controlled group is shown in Table 2. Patients 
with RHT as compared with controls were characterised by 
significantly higher LVMI and E’ velocity. 
Renal resistive index values were significantly higher 
in RHT patients than in patients with controlled HT 
(0.62 ± 0.05 vs. 0.60 ± 0.05, p = 0.042) (Fig. 1). There 
was no difference in PI between the groups. When subjects 
were divided according to gender, men with true RHT were 
characterised by significantly higher RRI and PI as compared 
with men with controlled HT (0.62 ± 0.05 vs. 0.59 ± 0.03, 
p = 0.001 and 1.1 ± 0.2 vs. 1.0 ± 0.1, p = 0.001, respec-
tively, for RRI and PI). No differences in RRI and PI values were 
found between women with true RHT and controlled HT.
In the RHT group RRI correlated significantly with age 
(r = 0.224, p = 0.006), clinic diastolic BP (r = –0.291, 
p = 0.001), daytime (r = –0.335, p < 0.001) and nighttime 
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(r = –0.305, p < 0.001) diastolic BP, clinic pulse pressure (PP) 
(r = 0.297, p = 0.001), daytime (r = 0.355, p < 0.001) and 
nighttime (r = 0.313, p < 0.001) PP, 24-h and daytime HR 
(r = –0.215, p = 013 and r = –0.182, p = 0.036, respectively) as 
well as with FPG (r = 0.215, p = 0.008) and E/E’ ratio (r = 0.289, 
p = 0.001). Both RRI and PI values were significantly higher in 
RHT patients with newly diagnosed diabetes as compared with 
RHT patients without diabetes (0.65 ± 0.05 vs. 0.62 ± 0.05, 
p = 0.022 and 1.2 ± 0.2 vs. 1.1 ± 0.2, p = 0.025, respectively) 
(Fig. 2). There was no correlation between RRI values and BP 
nocturnal decline. No differences in RRI values were found 
between dippers and non-dippers.
A multivariate stepwise linear regression model that in-
cluded variables correlated with RRI values at a significance 
of 0.05 or less was performed (Table 3). Age, daytime diastolic 
BP, and daytime PP and E/E’ ratio correlated independently 
with RRI in the model that included: age, daytime diastolic 
BP, daytime HR, daytime PP, FPG levels, and E/E’ ratio. 
For the analyses of our study population we took an RRI 
of 0.7 as a threshold, which is in agreement with other stud-
ies performed in hypertensive patients without renal disease 
or renal allograft, in which a threshold of 0.7 was applied. 
Increased RRI was found in 11 (7.3%) patients with true RHT 
and in one patient with well-controlled HT.  
Table 1. Clinical characteristics of patients with resistant hypertension (RHT) and control-group patients with well controlled 
hypertension (HT)
Characteristics RHT Controlled HT P
N 151 50
Males [%] 59.6 70.0 0.19
Age [years] 47.7 ± 10.4 46.8 ± 10.4 0.59
Clinic systolic BP [mm Hg] 159 ± 22 139 ± 22 < 0.001
Clinic diastolic BP [mm Hg] 96 ± 15 90 ± 14 0.051
Clinic PP [mm Hg] 63 ± 14 48 ± 15 < 0.001
Daytime systolic BP [mm Hg] 143 ± 18 130 ± 14 < 0.001
Daytime diastolic BP [mm Hg] 90 ± 13 82 ± 10 0.005
Daytime PP [mm Hg] 54 ± 11 48 ± 9 0.006
Daytime HR [bpm] 72 ± 11 70 ± 9 0.32
Nocturnal systolic BP [mm Hg] 129 ± 18 117 ± 13 < 0.001
Nocturnal diastolic BP [mm Hg] 78 ± 12 71 ± 8 < 0.001
Nocturnal PP [mmHg] 51 ± 11 47 ± 10 0.048
Nighttime HR [bpm] 66 ± 11 61 ± 7 0.020
Known history of hypertension [years] 10.7 ± 8.4 9.1 ± 6.7 0.26
Body mass index [kg/m2] 29.9 ± 4.7 27.8 ± 3.2 0.001
Abdominal obesity 72.2% 29.6% < 0.001
Metabolic syndrome 63.6% 34.8% < 0.001
Smoking [%] 17.9 18 0.55
Sodium [mmol/L] 142 ± 3 140 ± 3 0.005
Potassium [mmol/L] 4.4 ± 0.4 4.3 ± 0.5 0.61
Fasting glucose [mmol/L] 5.8 ± 0.9 5.4 ± 1.0 0.042
Creatinine [µmol/L] 79 ± 18 81 ± 16 0.39
GFR [mL/min/1.73 m2] 92.2 ± 16.1 93.9 ± 18.8 0.54
Uric acid [µmol/L] 354 ± 84 351 ± 80 0.84
Total cholesterol [mmol/L] 5.2 ± 1.1 5.1 ± 1.0 0.77
LDL-C [mmol/L] 3.3 ± 1.0 2.9 ± 1.1 0.019
HDL-C [mmol/L] 1.3 ± 0.4 1.8 ± 0.9 < 0.001
Triglycerides [mmol/L] 1.7 ± 1.1 1.5 ± 1.2 0.41
Number of antihypertensive medications 4 (3–5) 2 (1–3) < 0.001
The results are presented as mean ± one standard deviation or median and interquartile range in the parentheses. Categorical variables are shown 
as frequencies; BP — blood pressure; GFR — glomerular filtration rate; HDL-C — high-density lipoprotein cholesterol; HR — heart rate; LDL-C — 
low-density lipoprotein cholesterol; PP — pulse pressure
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Among patients with RHT, patients with increased RRI 
were characterised by older age, higher BMI, lower daytime 
and nighttime diastolic BP values, and lower daytime and 
nighttime HR as compared to patients with RRI < 0.7. The 
RHT patients with increased RRI as compared to patients with 
RRI < 0.7 were characterised also by higher daytime and night-
time PP. Both groups did not differ in respect of renal function 
(Table 4). There was a tendency towards higher E/E’ index as 
well as lower E’ velocity in patients with increased RRI (Table 5). 
DISCUSSION 
Our study showed that patients with true RHT were charac-
terised by higher clinic and ambulatory BP values, BMI and 
FPG concentration, and higher incidence of abdominal obesity 
Table 2. Echocardiographic parameters in patients with  
resistant hypertension (RHT) and control-group patients  
with well controlled hypertension (HT)




LVMI [g/m2] 125 ± 28 105 ± 25 < 0.001
LVH 51.0% 28.6% 0.010
LVEF [%] 70 ± 5 70 ± 7 0.82
E-wave [cm/s] 0.73 ± 0.19 0.75 ± 0.15 0.55
A-wave [cm/s] 0.79 ± 0.17 0.78 ± 0.15 0.76
E/A 1.15 ± 0.42 1.06 ± 0.27 0.11
E’ [cm/s] 10.4 ± 3.2 12.0 ± 3.8 0.020
E/E’ 8.1 ± 2.7 7.1 ± 2.5 0.062
The results are presented as mean ± one standard deviation. Catego-
rical variables are shown as frequencies; A-wave — late diastolic mitral 
flow velocity; E-wave — early diastolic mitral flow velocity; E’— early 
diastolic mitral annular velocity; LVH — left ventricular hypertrophy; 
LVEF — left ventricular ejection fraction; LVMI — left ventricular mass 
index
Figure 1. Renal resistive index values in patients with true 
resistant hypertension and in patients with well controlled 
essential hypertension; HT — hypertension
Figure 2. Renal resistive index values in patients with true 
resistant hypertension according to the presence of newly 
diagnosed diabetes mellitus; DM — diabetes mellitus
Table 3. Multivariate linear regression model (including age, 
daytime diastolic blood pressure, pulse pressure, daytime heart 
rate, daytime pulse pressure, fasting plasma glucose level,  
E/E’ ratio) for variables associated with renal resistive index
Parameter b standardised 
coefficient
P VIF
Age 0.214 0.009 1.15
Daytime DBP –0.394 < 0.001 1.35
Daytime PP 0.372 < 0.001 1.17
Daytime heart rate –0.126 0.13 1.25
FPG level 0.019 0.81 1.18
E/E’ ratio 0.169 0.034 1.35
DBP — diastolic blood pressure; FPG — fasting plasma glucose; PP — 
pulse pressure; VIF — variance inflation factors
and metabolic syndrome as compared to the subjects with 
well-controlled hypertension, confirming previous reports 
[22–24]. 
The clinical relevance of renal Doppler indices has been 
discussed extensively. In the present study significant differ-
ences in RRI values were found between patients with RHT 
and an age-matched, well-controlled hypertensive group. 
Also among patients with RHT, patients with increased 
RRI > 0.7 were characterised by older age, higher BMI, and 
lower daytime and nighttime diastolic BP values as compared 
to patients with RRI < 0.7.
More recently it has been suggested that RRI values may 
be related to increased BP and duration of the disease, and 
early organ damage in patients with essential HT, including 
RHT [2, 10, 21, 22]. 
It should be noted that our study, representing a cohort 
being evaluated, differs in some ways from previous re-
ports. We assessed a large group of patients with true RHT, 
characterised by moderately manifested target organ dam-
age, with preserved renal function and without history of 
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other cardiovascular diseases, which was compared with the 
age-matched controls with well-controlled HT. 
In other studies RRI was evaluated in patients with never 
treated or treated well-controlled essential HT, and in some of 
the studies they were older, had longer known duration of HT, 
and were characterised by higher prevalence of target organ 
damage. In a Veglio et al. [25] study including a relatively small 
group of 45 patients with essential HT it was shown that RRI 
was higher in subjects with a long-standing HT as compared to 
normotensive subjects and correlated with the severity and dura-
tion of the disease. The authors reported that baseline RRI was 
significantly higher in moderate and severe HT when compared 
to normal subjects and patients with mild HT [2, 10, 21, 25]. 
It should also be noted that some investigators evaluated 
RRI in patients with RHT but no comparison was performed 
with well-controlled subjects. The study of Raff et al. [10] 
showed that in patients with therapy-resistant hypertension 
RRI reflected functional and structural vascular parameters and 
measurement of RRI, in addition to other parameters, com-
plements screening for target organ damage in RHT therapy. 
However, patients with RHT were not compared with those 
with controlled HT [10].  
Table 4. Clinical characteristics of patients with resistant hypertension with normal and increased resistive index (RI)
Characteristics RI < 0.7 RI ≥ 0.7 P
N 140 11
Males [%] 58.6 72.7 0.36
Age [years] 47.3 ± 10.6 52.2 ± 4.9 0.012
Clinic systolic BP [mm Hg] 159 ± 22 160 ± 25 0.88
Clinic diastolic BP [mm Hg] 96 ± 15 91 ± 13 0.31
Clinic PP [mm Hg] 62 ± 14 68 ± 2 0.20
Daytime systolic BP [mm Hg] 143 ± 19 141 ± 14 0.66
Daytime diastolic BP [mm Hg] 90 ± 13 81 ± 8 0.030
Daytime PP [mm Hg] 53 ± 11 60 ± 13 < 0.001
Daytime HR [bpm] 73 ± 10 60 ± 7 < 0.001
Nocturnal systolic BP [mm Hg] 129 ± 18 129 ± 11 0.98
Nocturnal diastolic BP [mm Hg] 78 ± 12 72 ± 5 0.004
Nocturnal PP [mm Hg] 51 ± 11 57 ± 11 0.073
Nighttime HR [bpm] 73 ± 10 60 ± 7 < 0.001
Known history of hypertension [years] 10.6 ± 8.5 11.7 ± 6.9 0.68
Body mass index [kg/m2] 29.7 ± 4.5 32.8 ± 6.0 0.034
Abdominal obesity 71.4% 81.8% 0.46
Metabolic syndrome 62.9% 72.7% 0.51
Newly diagnosed diabetes 10% 18.2% 0.37
Smoking 17.2% 27.3% 0.40
Sodium [mmol/L] 142 ± 3 142 ± 1 0.86
Potassium [mmol/L ] 4.4 ± 0.4 4.3 ± 0.3 0.58
Fasting glucose [mmol/L] 5.7 ± 0.9 6.1 ± 0.8 0.23
Creatinine [µmol/L] 78 ± 18 81 ± 13 0.59
GFR [mL/min/1.73 m2] 92.4 ± 16.3 89.6 ± 13.9 0.58
Uric acid [µmol/L] 353 ± 85 364 ± 78 0.69
Total cholesterol [mmol/L] 5.2 ± 1.1 5.1 ± 1.1 0.84
LDL-C [mmol/L] 3.3 ± 1.0 3.5 ± 1.0 0.57
HDL-C [mmol/L] 1.3 ± 0.4 1.2 ± 0.3 0.28
Triglycerides [mmol/L] 1.7 ± 1.1 1.4 ± 0.8 0.48
Albuminuria [mg/24 h] 19.0 ± 18.9 21.2 ± 12.7 0.72
Number of antihypertensive medications 4 (3–5) 4 (3–5) 0.59
The results are presented as mean ± one standard deviation or median and interquartile range in the parentheses. Categorical variables are shown 
as frequencies; BP — blood pressure; GFR — glomerular filtration rate; HDL-C — high-density lipoprotein cholesterol; HR — heart rate; LDL-C — 
low-density lipoprotein cholesterol; PP — pulse pressure
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Also in contrast to our results, in most studied groups 
preserved renal function and lack of cardiovascular disorders, 
as pre-specified criteria, were not employed. Derchi et al. 
[26] examined renal vascular resistance in 291 untreated 
patients with essential HT. However, the prevalence of mild 
renal dysfunction was 63%, and the investigated patients were 
older, had higher systolic BP and PP, and were characterised 
by higher RRI than those with normal renal function [26].
Our study showed that RRI values in true RHT were 
significantly higher in patients with newly diagnosed diabetes 
as compared to those without diabetes. Our observation is 
supported by other studies indicating that dynamic evaluation 
of RRI may be an early detector of renal vascular alterations in 
the presence of type 2 diabetes and HT, even before the onset 
of microalbuminuria. Also, another prospective study showed 
that subclinical functional and structural renal abnormalities are 
predictors of new onset diabetes in patients with essential HT. 
It is noteworthy that in a model including all the renal param-
eters, RRI was the only significant independent risk factor for 
the development of diabetes during the study period [5, 12]. 
In our group of RHT patients significant correlation was 
found between RRI and FPG concentration, but no relation-
ship was found between RRI values and other features of 
metabolic syndrome, including abdominal obesity and dys-
lipidaemia.
It is noteworthy that in our group of RHT patients, signifi-
cant correlation between RRI and ambulatory daytime and 
nighttime diastolic BP was found. Of note, Pontremoli et al. 
[9] and other authors showed a positive correlation not with 
diastolic but with systolic BP in different groups of hypertensive 
patients [9, 27]. However, it should be noted that in the cur-
rent study BP measurements were documented by means of 
ambulatory BP. In a study by Raff et al. [10] including patients 
with therapy-RHT, systolic and diastolic BP as well as mean 
arterial pressure were not associated with RRI values. 
In our study in patients with RHT significant correlation 
was found between RRI value and both clinic and ambulatory 
PP. Also other investigators reported a significant relationship 
between RRI value and PP, a factor known to be associated 
with vascular stiffness [2, 28–30]. However, in the study by 
Raff et al. [10] including patients with therapy-RHT PP was 
not associated with RRI values [2, 10]. 
The positive correlation between RRI and PP and the 
negative correlation between RRI and diastolic BP could have 
been expected, given the formula used to calculate RRI. PP is 
regarded as a principal determinant of RRI and is influenced 
by cardiac function systemic arterial compliance. It has also 
been postulated that renal diastolic flow correlates with 
femoral-to-aortic pressure gradient (i.e. PP amplification) and 
with aortic distensibility linking arterial stiffness and RRI [29]. 
The present study did not show a significant relationship 
between RRI values and LVH or LVMI. Also, Pontremoli et al. [9] 
and Okura et al. [31] did not find any association between RRI 
and LVMI and LVH. Okura et al. [31] concluded that this could 
suggest that the mechanism of hypertension-mediated progres-
sive damage may differ between vessels and the myocardium. 
In a study by Tedesco et al. [32] a positive correlation was found 
between RRI values and LVMI. However, it should be noted 
that this group differs in some ways from patients included in 
our study and was distinguishing subjects with RRI < 0.7 from 
those with RRI > 0.7. The authors reported that hypertensive 
patients with RRI > 0.7 had increased LVMI with subclinical 
impairment of LV diastolic function [9, 31, 32].
In previous studies we found subclinical systolic and 
diastolic dysfunction in patients with RHT enrolled to the 
RESIST-POL Study. In the presented study RRI was signifi-
cantly and independently correlated only with E/E’ in RHT 
patients. In contrast Kuznetsowa et al. [30] demonstrated that 
RRI was significantly associated with LV systolic and diastolic 
Doppler parameters. This inconsistency in results may be 
secondary to differences in the groups of patients analysed 
in both of the studies [14, 15, 30].  
It should be noted that our results are based on an ob-
servational study and that longitudinal, prospective studies 
are needed to evaluate the predictive role of RRI in RHT pa-
tients. It should also be kept in mind that the associations we 
observed between RRI and clinic and ambulatory BP values, 
biochemical parameters, and echocardiographic parameters 
reflect a selected hypertensive group without history of other 
cardiovascular diseases, without known diabetes, and with 
preserved renal function. Therefore, the results of this study 
cannot be extrapolated to the whole group of patients with 
RHT. Other limitations of the study may include also a rela-
tively small group of patients with well-controlled HT.
Table 5. Echocardiographic parameters of patients with resistant 
hypertension with normal and increased resistive index (RI).
Characteristics RI < 0.7 RI ≥ 0.7 P
N 140 11
LVMI [g/m2] 123.4 ± 27.1 138.9 ± 37.5 0.078
LVH [%] 50.7 54.5 0.81
LVEF [%] 70.8 ± 8.8 69.8 ± 6.5 0.75
E-wave [cm/s] 0.78 ± 0.17 0.84 ± 0.13 0.79
A-wave [cm/s] 0.73 ± 0.18 0.74 ± 0.23 0.34
E/A 1.1 ± 0.42 1.2 ± 0.45 0.57
E’ [cm/s] 10.6 ± 3.2 8.8 ± 3.0 0.086
E/E’ 7.9 ± 2.4 10.8 ± 4.6 0.072
The results are presented as mean ± one standard deviation. Catego-
rical variables are shown as frequencies; A-wave — late diastolic mitral 
flow velocity; E-wave — early diastolic mitral flow velocity; E’ — early 
diastolic mitral annular velocity; LVH — left ventricular hypertrophy; 
LVEF — left ventricular ejection fraction; LVMI — left ventricular mass 
index
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CONCLUSIONS
In summary our study, evaluating cohort of patients with true 
RHT, indicates that patients with true RHT are characterised 
by significantly higher RRI values as compared with patients 
with well-controlled HT. It may also be suggested that in 
subjects with RHT renal vascular resistance is related to BP 
values, selected echocardiographic abnormalities, and some 
surrogate markers for metabolic and cardiovascular events, 
including FPG concentration and PP, respectively. 
The study was supported by the Ministry of Science and Higher 
Education NN 402 190 335.
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S t r e s z c z e n i e
Wstęp: Postuluje się, że zwiększony ultrasonograficzny wskaźnik oporowości przepływu w tętnicach wewnątrznerkowych (RRI) może być 
wykładnikiem rozwoju miażdżycy i powikłań narządowych nadciśnienia tętniczego zarówno w obrębie nerek, jak i całego organizmu. 
Cel: Celem pracy była ocena RRI i czynników związanych z jego wyższymi wartościami u chorych z prawdziwie opornym nadciś-
nieniem tętniczym (OPNT) włączonych do badania RESIST-POL.
Metody: Spośród 204 chorych z prawdziwie OPNT włączonych do badania RESIST-POL analizą objęto 151 osób (90 mężczyzn, 61 ko-
biet, średni wiek: 47,7 ± 10,4 roku, zakres: 19–65 lat), u których wykluczono wtórne postaci nadciśnienia tętniczego. Wszyscy chorzy 
charakteryzowali się zachowaną funkcją nerek (estymowany wskaźnik filtracji kłębuszkowej [eGFR] > 60 ml/min/1,73 m2) i brakiem 
wywiadu cukrzycy rozpoznanej przed włączeniem do badania. Grupę kontrolną stanowiło 50 dobranych pod względem wieku i płci 
pacjentów z dobrze kontrolowanym, pierwotnym nadciśnieniem tętniczym (35 mężczyzn, 15 kobiet, średni wiek: 46,8 ± 10,4 roku, 
zakres: 19–65 lat). Oceniane grupy nie różniły się także znanym czasem trwania nadciśnienia tętniczego. RRI oceniono w badaniu 
doplerowskim tętnic nerkowych. Za wartość podwyższoną uznano RRI ≥ 0,7.
Wyniki: Chorzy z prawdziwie OPNT charakteryzowali się wyższym RRI w porównaniu z pacjentami z dobrze kontrolowanym nadciśnieniem 
tętniczym pierwotnym (0,62 ± 0,05 vs. 0,60 ± 0,05; p < 0,05). Porównywane grupy nie różniły się pod względem parametrów funkcji 
nerek — stężenia kreatyniny w osoczu (78,6 ± 17,7 vs. 81,1 ± 16,1 µmol/l; p = 0,39) i eGFR (92,2 ± 16,1 vs. 93,9 ± 18,8 ml/min/1,73 m2; 
p = 0,54). W grupie chorych z prawdziwie OPNT wartości RRI korelowały istotnie z: wiekiem, wartościami rozkurczowego ciśnienia 
tętniczego (DBP) i ciśnienia tętna w pomiarach klinicznych oraz w całodobowej rejestracji ciśnienia tętniczego, jak również ze stężeniem 
glukozy na czczo (r = 0,215; p = 0,008) oraz ze wskaźnikiem E/E’ (r = 0,289; p = 0,001) w badaniu echokardiograficznym. Wiek, 
wartości DBP oraz ciśnienia tętna z okresu dnia w całodobowej rejestracji oraz wskaźnik E/E’, ale nie stężenie glukozy na czczo, korelo-
wały niezależnie z RRI w analizie wieloczynnikowej w grupie chorych z prawdziwie OPNT. Podwyższony RRI stwierdzono u 11 chorych 
z prawdziwie OPNT (7,3%) i u 1 pacjenta z dobrze kontrolowanym nadciśnieniem tętniczym pierwotnym (2%). Chorzy z prawdziwie 
OPNT z podwyższonym RRI w porównaniu z pacjentami z prawdziwie OPNT i prawidłowym RRI charakteryzowali się starszym wiekiem 
(52,2 ± 4,9 vs. 47,3 ± 10,6 roku; p = 0,012), wyższym wskaźnikiem masy ciała (32,8 ± 6,0 vs. 29,7 ± 4,5 kg/m2; p = 0,034), a także 
niższymi wartościami DBP z okresu dnia i nocy oraz wyższym ciśnieniem tętna z okresu dnia i nocy w całodobowej rejestracji ciśnienia 
tętniczego. Chorzy z prawdziwie OPNT z podwyższonym i prawidłowym RRI nie różnili się pod względem stężenia kreatyniny oraz eGFR. 
Wnioski: Wyniki wskazują, że chorzy z prawdziwie OPNT mogą się charakteryzować istotnie wyższymi wartościami RRI w porów-
naniu z pacjentami z dobrze kontrolowanym nadciśnieniem tętniczym pierwotnym, jak również że wartości RRI u chorych z praw-
dziwie OPNT mogą korelować z wartościami ciśnienia tętniczego i ciśnienia tętna oraz z wybranymi parametrami metabolicznymi 
i echokardiograficznymi.
Słowa kluczowe: nadciśnienie tętnicze oporne, wskaźnik oporowości, cukrzyca, powikłania narządowe, ciśnienie tętna
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